Immunosuppressive agents and cytomegalovirus infection

Archivum Immunologiae et Therapiae Experimentalis

Volumn 51, Issue 3, 2003, Pages 179-184

  Tanaka, Kazuo ^a  

^a TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Cytomegalovirus; Immunosupression; MHC antigen tetramer; Transplantation; Virus specific T cell

Indexed keywords

AZATHIOPRINE; CALCINEURIN INHIBITOR; CD4 ANTIGEN; CD8 ANTIGEN; CHIMERIC ANTIBODY; CORTICOSTEROID; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 2 RECEPTOR ANTIBODY; LYMPHOCYTE ANTIBODY; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; POLYCLONAL ANTIBODY; PREDNISOLONE; RAPAMYCIN; T LYMPHOCYTE ANTIBODY; TACROLIMUS; THYMOCYTE ANTIBODY;

ALLOTRANSPLANTATION; CYTOMEGALOVIRUS INFECTION; DRUG MECHANISM; FLOW CYTOMETRY; GRAFT REJECTION; HUMAN; IMMUNE DEFICIENCY; IMMUNOSUPPRESSIVE TREATMENT; INFECTION COMPLICATION; ORGAN TRANSPLANTATION; PERSISTENT VIRUS INFECTION; REVIEW; T LYMPHOCYTE; VIRUS REACTIVATION;

ANIMALS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; HERPESVIRIDAE; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; MICE; ORGAN TRANSPLANTATION; T-LYMPHOCYTES; TIME FACTORS;

EID: 0037673176     PISSN: 0004069X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (28)

1. BABEL N., KERN F., VOLK H.-D. and REINKE P. (2002): Cytomegalovirus infections in kidney transplant patients. Transplant. Rev., 16, 121-130.
2. BUKOWSKI J. F., WODA B. A. and WELSH R. M. (1984): Pathogenesis of murine cytomegalovirus infection in natural killer cell-depleted mice. J. Virol., 52, 119-128.
3. DE MAAR E. F., VERSCHUUREN E. A., HOMAN VD HEIDE J. J., KAS-DEELEN D. M., JAGERNATH D., THE T. H., PLOEG R. J. and VAN SON W. J. (2002): Effects of changing immunosuppressive regimen on the incidence, duration, and viral load of cytomegalovirus infection in renal transplantation: a single center report. Transpl. Infect. Dis., 4, 17-24.
4. European Mycophenolate Mofetil Cooperative Study Group (1995): Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. Lancet, 345, 1321-1325.
5. + T lymphocytes in healthy seropositive donors. J. Virol., 74, 8140-8150.
6. HIBBERD P. L., TOLKOFF-RUBIN N. E., COSIMI A. B., SCHOOLEY R. T., ISAACSON D., DORAN M., DELVECCHIO A., DELMONICO F. L., AUCHINCLOSS H. JR. and RUBIN R. H. (1992): Symptomatic cytomegalovirus disease in the cytomegalovirus antibody seropositive renal transplant recipient treated with OKT3. Transplantation, 53, 68-72.
7. HO M. (1990): Epidemiology of cytomegalovirus infections. Rev. Infect. Dis., 12 (suppl. 7), S701-S710.
8. JONJIC S., PAVIC I., POLIC B., CRNKOVIC I., LUCIN P. and KOSZINOWSKI U. H. (1994): Antibodies are not essential for the resolution of primary cytomegalovirus infection but limit dissemination of recurrent virus. J. Exp. Med., 179, 1713-1717.
9. KAHAN B. D., RAJAGOPALAN P. R., HALL M. and United States Simulect Renal Study Group (1999): Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2-receptor monoclonal antibody. Transplantation, 67, 276-284.
10. KHAN N., SHARIFF N., COBBOLD M., BRUTON R., AINSWORTH J. A., SINCLAIR A. J., NAYAK L. and MOSS P. A. H. (2002): Cytomegalovirus seropositivity drives the CD8 T cell repertoire toward greater clonality in healthy elderly individuals. J. Immunol., 169, 1984-1992.
11. KLENERMAN P., CERUNDOLO V. and DUNBAR P. R. (2002): Tracking T cells with tetramers: new tales from new tools. Nat. Rev. Immunol., 2, 263-272.
12. KUYPERS D. R., EVENEPOEL P., MAES B. D., COOSEMANS W., PIRENNE J. and VANRENTERGHEM Y. F. (2002): Role of immunosuppressive drugs in the development of tissue-invasive cytomegalovirus infection in renal transplant recipients. Transplant. Proc. 34, 1164-1170.
13. NITSCHE A., STEUER N., SCHMIDT C. A., LANDT O., ELLERBROK H., PAULI G. and SIEGERT W. (2000): Detection of human cytomegalovirus DNA by real-time quantitative PCR. J. Clin. Microbiol., 38, 2734-2737.
14. NODA S., TANAKA K., SAWAMURA S., SASAKI M., MATSUMOTO T., MIKAMI K., AIBA Y., HASEGAWA H., KAWABE N. and KOGA Y. (2001): Role of nitric oxide synthase type 2 in acute infection with murine cytomegalovirus. J. Immunol., 166, 3533-3541.
15. PODLECH J., HOLTAPPELS R., PAHL-SEIBERT M.-F., STEFFENS H.-P. and REDDEHASE M. J. (2000): Murine model of interstitial cytomegalovirus pneumonia in syngeneic bone marrow transplantation: persistence of protective pulmonary CD8-T-cell infiltrates after clearance of acute infection. J. Virol., 74, 7496-7507.
16. REDDEHASE M. J. (2000): The immunogenicity of human and murine cytomegaloviruses. Curr. Opin. Immunol., 12, 360-396.
17. RUBIN R. H. (1994): Infection in the organ transplant recipient. In RUBIN R. H. and YOUNG L. S. (eds.): Clinical approach to infection in the compromised host. 3rd. edition. Plenum Medical Book Company, New York, 629-705.
18. SARMIENTO J. M., MUNN S. R., PAYA C. V., VELOSA J. A. and NGUYEN J. H. (1998): Is cytomegalovirus infection related to mycophenolate mofetil after kidney transplantation? A case-controlstudy. Clin. Transplant., 12, 371-374.
19. SESTER M., SESTER U., GÄRTNER B., HEINE G., GIRNDT M., MUELLER-LANTZSCH N., MEYERHANS A. and KÖHLER H. (2001): Levels of virus-specific CD4 T cells correlate with cytomegalovirus control and predict virus-induced disease after renal transplantation. Transplanation, 71, 1287-1294.
20. SESTER M., SESTER U., GARTNER B., KUBUSCHOK B., GIRNDT M., MEYERHANS A., and KÖHLER H. (2002): Sustained high frequencies of specific CD4 T cells restricted to a single persistent virus. J. Virol., 76, 3748-3755.
21. + mononuclear cells. J. Immunol., 143, 2873-2879.
22. TANAKA K., KOGA Y., LU Y. Y., ZHANG X. Y., WANG Y., KIMURA G. and NOMOTO K. (1994): Murine cytomegalovirus associated pneumonitis in the lungs free of the virus. J. Clin. Invest., 94, 1019-1025.
23. TANAKA K., NAKAZAWA H., OKADA K., UMEZAWA K., FUKUYAMA N. and KOGA Y. (1997): Nitric oxide mediates murine cytomegalovirus-associated pneumonitis in lungs that are free of the virus. J. Clin. Invest., 100, 1822-1830.
24. TANAKA K., NODA S., SAWAMURA S., KABIR A. M. and KOGA Y. (2001): Nitric oxide targets bronchiolar epithelial cells in murine cytomegalovirus-associated disease in lungs that are free of the virus. Arch. Virol., 146, 1499-1515.
25. TANAKA K., TILNEY N. L., STUNKEL K. G., HANCOCK W. W., DIAMANTSTEIN T. and KUPIEC-WEGLINSKI J. W. (1990): Pretreatment with cyclosporine and anti-interleukin 2 receptor antibody abrogates the anti-idiotype response in rat recipients of cardiac allografts. Proc. Natl. Acad. Sci. USA, 87, 7375-7379.
26. TER MEULEN C. G., WETZELS J. F. and HILBRANDS L. B. (2000): The influence of mycophenolate mofetil on the incidence and severity of primary cytomegalovirus infections and disease after renal transplantation. Nephrol. Dial. Transplant., 15, 711-714.
27. TILNEY N. L. and STROM T. B. (1988): Chemical manipulation of the immune responses. In CERILLI G. (ed.): Organ transplantation and replacement. Lippincott Company, Philadelphia, 118-136.
28. ZAIA J. A. (1994): Cytomegalovirus infection. In FORMAN S. J., BLUME K. G. and THOMAS E. D. (eds.): Bone marrow transplantation. Blackwell Scientific publications, Boston, 377-403.